Form 4: Abbott Laboratories Director, Patricia Paola Gonzalez, Reports Acquisition of Restricted Stock Units

Patricia Paola Gonzalez, a director of Abbott Laboratories, reported the acquisition of 1,866 restricted stock units on April 26, 2024.

Summary

• On April 26, 2024, Patricia Paola Gonzalez, a director of Abbott Laboratories, acquired 1,866 common shares without par value, in the form of restricted stock units, at a price of $0.
• Following the transaction, Gonzalez directly owns 5,284 common shares.
• These restricted stock units were awarded under the Abbott Laboratories 2017 Incentive Stock Program and will be paid in Abbott common shares on a one-to-one basis upon separation from service, death, or a change in control.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of restricted stock units by a director generally indicates confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of restricted stock units by a director signals confidence in the company's future performance.

Future Outlook

The restricted stock units will be paid out in Abbott common shares upon the director's separation from service, death, or a change in control, as defined in the Abbott Laboratories 2017 Incentive Stock Program.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors, and their confidence in the company's stock.

Stakeholder Impact

• The acquisition of restricted stock units by a director can positively influence shareholder sentiment.

Key Dates